Improving chronic pain care
with a personalized medicine approach
Explore more
The Company
- Iremis therapeutics is a clinical stage company, spin-off of the University of Geneva and the University Hospital of Geneva, launched in 2024.
- The goal of the company is to develop innovative therapeutic and theranostic solutions for the treatment of neuropathic pain and other chronic pain conditions.
- Its lead molecule IRX-001 is in Phase 2 clinical development.
- Iremis therapeutics maintains a lean structure to optimize its growth.
- Iremis therapeutics main program has received a funding from Innosuisse, the Swiss Innovation Promotion Agency.
Our Missions
- Iremis therapeutics develops therapeutic solutions to treat chronic pain with a personalized medicine approach, aiming at fulfilling unmet medical needs. It optimizes pharmacologically the use of molecules to achieve increased benefits for patients and identifies appropriate indications for α2 GABA preferred agonists such as NDMC for patients with chronic pain.
- Iremis therapeutics implements evidence-based guidelines for dosage and administration of NDMC in adult populations based on patient age, resistance to first line therapy, severity of symptoms, metabolism and co-morbidities.
- Iremis therapeutics assesses patient response to NDMC therapy through regular monitoring of symptom improvement and the emergence of adverse effects.
- Iremis therapeutics collaborates with other healthcare professionals to manage chronic neuropathic pain and comprehensively addresses patient concerns to optimize NDMC therapy.
- Iremis therapeutics applies pharmacogenetic to adapt dosing to specific populations.
Who We Are
François Curtin, founder and chairman of the Board, has a long experience in drug development in pharmas and biotechs. Former CMO Personalized Health at ETHZ and former CEO of Geneuro SA, François launched two other startups: AURA AS and Cresence AS with two successful exits. He manages the company and is in charge of the clinical development.
Jules Desmeules, founder and member of the Board is the former Head of the Division of Clinical Pharmacology and Toxicology and the Pain center at the Geneva University Hospital. His main research topic is the implementation of personalized medicine and pharmacogenetic in chronic pain treatment, the development of neuro-physiological evaluation methods for testing the efficacy of peripheral and central analgesics – he is one of the inventors of NDMC. Jules is the CSO of the company.
Hongguang Dong, founder and member of the Board is the manager of an integrative clinic of Traditional Chinese medicine in Geneva. He is the vice president of the Mondial Acupuncture Society and has a tremendous experience in the treatment of patients suffering from chronic pain conditions. Hongguang has a strong network in business and academia in China. He is the Chief Business Officer of the company.
James Wampfler, founder and member of the Board has 30 years of management experience in nursing home centers. He is a founding and former board member of the Geneva Federation of Elderly Homes. He is the sponsor of clinical trials testing new chemical entities for conditions encountered in elderly populations. James is the CFO of the company.